Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
Patent 5639738 Issued on June 17, 1997. Estimated Expiration Date: June 17, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
A method of treating a mammal for a condition of the skin or exposed tissue selected from the group consisting of basal cell carcinoma and actinic keratosis is provided. The method consists essentially of topically administering to the site of the condition, more than once per day over a period of days sufficient to treat the condition, a non-toxic effective dosage amount of a composition consisting essentially of(a) a non-steroidal anti-inflammatory drug (NSAID) in an amount sufficient to block prostaglandin synthesis,(b) hyaluronic acid or a pharmaceutically acceptable salt thereof in an amount effective to transport said NSAID into the skin or exposed tissue at the site of the condition. The concentration of the hyaluronic add or salt thereof is between 1-3% by weight of the composition. The molecular weight of the hyaluronic acid or salt thereof is between 150,000 and 750,000 Daltons. A pharmaceutical excipient suitable for topical application is included. The NSAID in the composition may be diclofenac sodium.
Other References
Kelley, RS et al Complete Spontaneous Regression of Multiple Basal Cell Carcinomas in Basal Cell Nevus Syndrome: Possible Role of Transepithelial Elimination J. Dermatol. Surg. Oncol. 16(11) 1039-42 1990
Reynolds et al (ed.) "Martindale The Extra Pharmacopoeia", (1982)
The Pharmaceutical Press, London, pp. 234-235
West et al (1989) Exp. Cell Res. 183:179-196
Alho et al (1989) J. Cell Biol. 108:1557-1565
U.S. Application No. 07/338,106, Falk Filed Apr. 1989
Sandra Blakeslee, "Solid cores of tumors keeping out best drugs", Jul. 8, 1989 edition of the Globe and Mail, Toronto, Ontario, p. D4
Pam Harrison, "Toxic drug tamed but still potent" Ontario Medicine, vol. 8, No. 16 dated Aug. 21, 1989, p. 1
The Merck Index Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, pp. 751 and 752 1989
Braun, D. P. et al. Alan R. Liss, Inc., Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists, Immunity to Cancer II, 1989, pp. 439-448
Goodwin, J.S. Prostaglandin E and Cancer Growth Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, Augmentive Agents in Cancer Therapy, Raven Press, New York, (1981)
Dr. Samuel Asculai, "Inactivation of Herpes Simplex Viruses by Nonionic Surfactants", Antimicrobial Agents and Chemotherapy, Apr. 1978, pp. 686-690
Chemical Abstracts, vol. 76, No. 10; W. E. Sneader; "Possible Mechanism for action of DMSO on Percutaneous absoption", J. Pharm. Pharmcol, 1971, 23 (Supp)
Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967(9): 967-969
Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellular Matrix vol. III. New York: Academic Press, 1970, pp. 1241-1253
Balazs EA, Band P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries. Polymers in Cosmetics 1984; 99: 65-72
Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodoium hyaluronate Acta Pharmaceutica Suecica 1985; 22(6): 315-320
Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current Eye Research 1987; 6(6): 779-784
Chang S-C. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit. Dissertation Abstracts International 1988; 49(2): 367-B
Cravioto, R.O., et al. Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid From Vitreous Humor in Depressing Blood-Sugar Levels Science (1950); vol. 111: 520-521
Gieldanowski, Jerzy; Skowronska, Jadwiga Studies on immunosuppressive and anti-inflammatory effect of adriamycin. Arch. Immunol. Ther. Exp. (1980); 28 (3): 439-446
Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 384-388
Hurd ER Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate. Arthritis and Rheumatism (1973 Jan.-Feb.); 16 (1): 84-88
Idson B. Polymers in skin cosmetics. Cosmetics & Toiletries 1988; 103: 63-68
Johansson A, Hassan H, Renck H. Effects of adjuvants to local anaesthetics on their duration Acta Anaesthesiol Scand. 1985; 29: 736-738
Kalbhen D.A. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon.RTM.). Z. Rheumatol (1982); 41: 202-211
Katsu M., Abe T., Shimada S. Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence. Nippon Rinsho (1968 Jan.); 26(1): 89-95
Kreis H, Chkoff N, Droz D, et al. Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients. Transplantation (1984 Feb.); 37(2): 139-145
McIlwraith W. Current concepts in equine degenerative joint disease. Journal of the American Veterinary Medical Association (1982); Feb. 1: 239-250
Mizushima, Y. Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future. Nippon Rinsho (Jan. 1986); 26(1): 61-65
Nizolek DJH, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review. The Cornell Veterinarian 1981: 71(4): 355-375
Pigman W, et al. Acide hyaluronique et facteurs de permeabilite tissulaire. Bull. Soc. Chim. Biol. 1963; 45(2-3): 185-202
Pruett RC, Schempens CL, Constable IJ, Swann DA. Hyaluronic acid vitreous substitute. In: Vetreous Surgery and Advances in Fundus Diagnosis and Treatment. Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444
Reim M, Teping C. Surgical procedures in the treatment of most severe eye burns. Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54
Rydell NW, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clinical Orthopaedics and Related Research 1971; 80(Oct.): 25-29
Saba P, Galeone F, Salvadorini F, Guarguaglini M, Ombrato M. Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex. Current Therapeutic Research 1978; 23(4): 455-463
Stegman R, Miller D. Use of sodium hyaluronate in severe penetrating ocular trauma. Acta Ophthalmol. 1986; 18: 9-13
Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al. Prevention of wound dehiscence in severely obese patients with jejuno-ileal by-pass: The role of hyaluronic acid. Pharmatherapeutica 1988; 5(4): 233-239
Sertoli P, Merello A, Parodi M. L'acido jaluronico, per uso topico, nella cura delle ulcere trofo-circolatorie degli arti inferiori. (Comunicazioni). Giornale Italiano di Dermatologia 1970; 45(8): 468-471
Walther, M. The Prevention of Strine Cutis Distansae During Pregnancy. Mineva Gynecolgia (1981) vol. 33; 497-499
Weirich, E.G., Longauer, J.K., Kirkwood, A.H. Dermatopharmacology of salicylic acid. III. Topical contra-inflammatory effect of salicylic acid and other durgs in animal experiments. Dermatologica (1976); 152: 87-9
June 17, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
